Category: Articles

Histologics LLC Releases SoftBiopsy®+D, the Versatile Kylon® Fabric-Tipped Device for Wound Debridement or Tissue Biopsy Sampling

ANAHEIM, Calif.July 5, 2023 /PRNewswire/ — Histologics LLC attended “WOCNext” in Las Vegas last June 4-6th to exhibit its novel debridement and wound biopsy fabric-curettage devices including for the first time, the SoftBiopsy®+D device. Over 1M cases by clinicians used Kylon® devices for colposcopic biopsy and curettage in the USA, in nearly every clinical setting The hooked medical (Kylon®) fabric tipped brushes gently remove and can trap tissue for biopsy for histology or microbiology. The debridement may be performed at a lighter “hygiene” level, extending all the way to “excisional” surgical methods when the brush array converts to micro-curettes if the fabric is pressed firmly and wiped or twisted into tissue.

Kylon® Fabric Debridement and Biopsy : Video Simulation

The cause of some wounds not to heal includes biofilm, and the Kylon® fabric devices can be used to obtain true tangential biopsy samples from the debrided wound base for lab testing.  This is commonly done with the SoftBiopsy® product, solely used for biopsy that is sent to a laboratory. Histologics recently released SoftBiopsy®+D, a more versatile and durable version for clinicians, that can sustain longer procedure time for wound debridement as well as biopsy.

We have previously demonstrated the value of our Soft K-Rette® device to debride and sample crevice wounds, and Soft K-Cot® deployed on the finger for “Compassionate Debridement at Your Fingertips®”.

The scope of practice of most physicians and nurse clinicians vary from basic wound care to the most advanced surgical procedures where necrotic wound tissue must be mechanically or surgically removed.  Advanced and basic wound care providers include many specialties in health care and procedures occur in clinics, hospitals, homes, facilities and other settings. Some providers that shy away from regular debridement (necessary to heal wounds) due to the invasive nature of the scalpel and sharp curette would be willing to clean wounds using the gentle  Kylon® devices.

Please visit our wound care website to request free samples at,  or contact Lily Ramos at, Toll Free:  888-235-2275.

SOURCE Histologics LLC

Metabolic memory in diabetic foot syndrome (DFS): MICRO-RNAS, single nucleotide polymorphisms

(SNPs) frequency and their relationship with indices of endothelial function and adipo-inflammatory dysfunction Alessandro Del Cuore, Rosaria Maria Pipitone, Alessandra Casuccio, Marco Maria Mazzola, Maria Grazia Puleo, Gaetano Pacinella, Renata Riolo, Carlo Maida, Tiziana Di Chiara, Domenico Di Raimondo, Rossella Zito, Giulia Lupo, Luisa Agnello, Gabriele Di Maria, Marcello Ciaccio, Stefania Grimaudo & Antonino Tuttolomondo

Revolutionizing Podiatry for Efficient Patient Care

As the director of podiatric medical education and co-chief of the podiatry division, I lead certified residency and fellowship training in wound care along with our parent organization, Council on Podiatric Medical Education. We are a renowned healthcare organization specializing in podiatry and a broad range of primary care and specialty services …

Nuo Therapeutics’ Aurix® System Added To Wound Care Formulary Of Wound Care Advantage

HOUSTON, June 22, 2023 (GLOBE NEWSWIRE) — Nuo Therapeutics, Inc. (OTCQB: AURX) (“Nuo”), a commercial stage medical device company pioneering leading-edge biodynamic therapies by focusing on emerging opportunities in the evolving healthcare landscape, is pleased to announce that Wound Care Advantage (WCA), the nation’s leading wound care consulting firm has added the Aurix® System to its formulary. Founded in 2002, Wound Care Advantage (WCA) has established a large network of successful wound healing programs with partner hospitals. Through a strong commitment to quality care and innovation, WCA has built financially sustainable wound care programs that have saved limbs and lives of more than 40,000 patients suffering chronic wounds.

“Diabetic foot ulcers pose a significant risk to patients and can be challenging for wound care centers to treat from both clinical and financial perspectives,” commented Dave Hazard, Nuo’s Vice President of Sales. “With thousands of commercially available wound care products, it can be extremely difficult for wound care centers to identify products that are both reimbursed by Medicare, and more importantly, that actually heal patients. We are excited to partner with Wound Care Advantage’s team of experts who rigorously vet each product that is placed on the formulary.”

The Platelet Rich Plasma gel produced by the Aurix System is cleared by the FDA for treating chronic wounds with a simple one-minute spin. In a clinical study performed with the Centers for Medicare and Medicaid Services (CMS), the Aurix System demonstrated a higher healing rate and a significant time to heal advantage as compared to other advanced healing modalities.

About Nuo Therapeutics

Nuo Therapeutics, Inc. is a commercial stage medical device company pioneering leading-edge biodynamic therapies by focusing on emerging opportunities in the evolving healthcare landscape. The Company’s Aurix System is a biodynamic hematogel that harnesses a patient’s innate regenerative abilities for the management of a variety of wounds.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements. These forward-looking statements may include statements that are predictive in nature and depend upon or refer to future events or conditions, and may include words such as “believes,” “plans,” “anticipates,” “projects,” “estimates,” “expects,” “intends,” “strategy,” “future,” “opportunity,” “may,” “will,” “should,” “could,” “potential,” or similar expressions. You are cautioned not to unduly rely on forward-looking statements. Forward-looking statements are based on current expectations, assumptions, and information available to the Company’s management and are subject to known and unknown risks, uncertainties and other factors which may cause actual results to differ materially from the forward- looking statements. These risks, uncertainties, and factors are discussed under “Risk Factors” and elsewhere in the Company’s public filings with the U.S. Securities and Exchange Commission from time to time, including the Company’s annual report on Form 10-K, quarterly reports on Form 10-Q, and current reports on Form 8-K. You are advised to carefully consider these various risks, uncertainties, and other factors. The Company expressly disclaims any intent or obligation to update or revise publicly these forward-looking statements except as required by law.

David Jorden

Seasoned Healthcare Executive David Bassin Joins the MolecuLight Board of Directors

Former Healogics CEO Brings Deep Wound Care Industry Experience to MolecuLight’s
Rapidly Growing Business

TORONTOJuly 6, 2023 /PRNewswire/ – MolecuLight Inc., the leader in point-of-care fluorescence imaging that locates and detects elevated, pathogenic bacterial loads in and around wounds, is pleased to announce the appointment of David Bassin to its Board of Directors as an Independent Board Member.

David Bassin brings a wealth of expertise and experience in the healthcare industry, particularly in the field of wound care. As the founder of GIO Advisory LLC, he has provided invaluable advisory services to numerous companies and private equity firms based on his extensive background in healthcare, spanning pharmaceutical/device, payer, and provider services. Most recently, Bassin served as the CEO of Healogics, the foremost provider of wound care services in the US, operating over 630 wound care centers and 300 providers. During his tenure, he successfully restructured and refocused the business, resulting in strong earnings growth prior to his transition into advisory services. Prior to his role as CEO, Bassin served as the CFO of Healogics, contributing to the company’s financial growth and success. Bassin’s impressive career also includes significant roles in other healthcare organizations. He served as the CFO of eviCore Healthcare, Inc., where he oversaw multiple dividend recapitalizations and facilitated a merger with the company’s largest competitor, leading to the creation of a company with over 3,000 employees. Additionally, Bassin held the position of CFO at InVentiv Health, Inc., a provider of services to pharmaceutical companies, where he successfully managed a high-growth company and orchestrated a go-private transaction valued at over $1 billion and delivered a significant premium to its shareholders.

“We are thrilled to welcome David Bassin to the MolecuLight Board of Directors,” said Anil Amlani, CEO of MolecuLight. “His extensive experience in optimizing and scaling organizations across the healthcare industry, particularly in wound care, will be invaluable to MolecuLight as we continue to expand our global presence. Our MolecuLight devices have already become indispensable tools in wound assessment and real-time decision-making for thousands of clinicians worldwide. David’s expertise will greatly support our mission to meet the increasing global demand for our innovative wound care diagnostics and establish them as the gold standard in the field.”

David Bassin expressed his excitement about joining MolecuLight’s Board of Directors, stating, “There are over 6.5 million patients living with wounds.  As an industry, we need to continue to develop new solutions that improve wound care treatment effectiveness and efficiency.  With a global drive to improve outcomes, reduce costs, and minimize antibiotic usage, MolecuLight’s point-of-care devices have demonstrated their ability to effectively address these critical clinical needs. I am deeply impressed by the organization, the technology’s alignment with market demands, and the significant market traction they have achieved. I am eager to contribute to their growth and help them achieve their ambitious goals.”

MolecuLight’s groundbreaking i:X® and DX™ imaging devices are the only FDA-cleared and CE and Health Canada approved devices for the real-time detection of elevated bacterial burden in wounds. Supported by over 80 peer-reviewed publications involving 2,600 patients, these devices are widely utilized by leading wound care facilities worldwide.

About MolecuLight Inc.

MolecuLight Inc. is a privately-owned medical imaging company that has developed and is commercializing its proprietary fluorescent imaging platform technology in multiple clinical markets. MolecuLight’s commercial devices, which include the MolecuLight i: and DX™ fluorescence imaging systems and their accessories, are point-of-care handheld imaging devices for the real-time detection and localization of bacterial load in wounds and digital wound measurement. MolecuLight procedures performed in the United States benefit from an available reimbursement pathway which includes two CPT® codes for physician work to perform “fluorescence imaging for bacterial presence, location, and load” and facility payment for Hospital Outpatient Department (HOPD) and Ambulatory Surgical Center (ASC) settings through an Ambulatory Payment Classification (APC) assignment. The company is also commercializing its unique fluorescence imaging platform technology for other global markets with relevant unmet needs in food safety, consumer cosmetics and other key industrial markets.

For more information, contact:

Rob Sandler 
Chief Marketing Officer
MolecuLight Inc.
T. +1.647.362.4684


SOURCE MolecuLight

The Wound Company Launches With $4.25M In Funding To Curb the Amputation Epidemic And Save The Healthcare System Billions

Led by Susa Ventures and Sozo Ventures, the funding will be used to transform the $45B wound and ostomy care industry by bringing on-demand experts to more patients and providers in need via telehealth and in-person visits


Minneapolis, MN – WEBWIRE – Thursday, June 15, 2023

The Wound Company, a multi-channel on-demand wound and ostomy care delivery company that improves patient outcomes, today announced its launch from stealth with $4.25M in seed funding from Susa Ventures and Sozo Ventures. The funding will be used to expand the company’s national footprint, hire top talent, and to continue improving health outcomes in the most cost-effective way possible while bringing dignity to the over 13 million people in need of improved wound and ostomy care.

Why Wound Care Matters

The US is experiencing an amputation epidemic due to diabetic foot ulcers and other serious wounds. Despite medical advancements, Americans are amputating double the number of limbs today than during the Civil War. About 50% of lower extremity amputations would have been preventable if patients with type 2 diabetes and foot ulcers had access to better healthcare. This issue is one of the problems The Wound Company is solving for.

Often providers need more wound care expertise or, due to understaffing, don’t have time to offer comprehensive care continuously, leaving patients to figure it out on their own. This leads to wound care patients returning to the hospital due to improper wound care. But it can be prevented.

“The wound and ostomy care industry is broken,” said Nima Ahmadi, founder and CEO of The Wound Company. “It’s operating in the fee-for-service world, which pushes expensive procedures and products that help the bottom line, but don’t impact outcomes for the patient. We’re paid to heal wounds with continuous care and, in doing so, save money for health plans and at-risk providers.”

Enter The Wound Company

The Wound Company aims to fix the broken space of wound and ostomy care by using predictive analytics and multi-channel communications to deliver the right wound and ostomy care to the right patient in the right channel at the right time. The tech connects patients and providers to wound and ostomy experts virtually or via in-person visits to ensure they have top-tier care.

“The Wound Company’s innovative technologies have the potential to save health plans billions of dollars and transform the patient experience,” says Susa Ventures Investor Derick En’Wezoh. “With a dedicated team of highly experienced experts, a strong vision, and a passion for improving healthcare outcomes, this tech will save lives.”

The platform also offers clinical reporting, customer data integration, and workflow automation to make care delivery as painless as possible for providers.

While in stealth, The Wound Company has already partnered with health plans, health systems, home care providers, hospice providers, and patients, with significant results to date:

  • A potential 15-20% reduction in the total cost of care for wound and ostomy patients for payers
  • Up to 50% savings on supplies per patient for home and hospice care providers
  • 60% of patients demonstrated progressive healing week after week
  • 90% of Stage I/II pressure ulcers resolved without advancing to a higher stage
  • 100% of ostomy patients have a predictable pouching system and reduced chance of ER visits or readmissions


“Our blend of virtual and in-person services provided by passionate experts in wound care helps people heal quickly, safely, and with the dignity they deserve while helping to alleviate the pressure on overworked healthcare professionals,” said Chief Medical Officer Sanford Roberts.

The Wound Company is open to partnerships with health plans, at-risk providers, home health providers, and hospice care providers. For more information, visit

About The Wound Company

The Wound Company is a Minneapolis-based technology company dedicated to advancing wound and ostomy care. The company uses proprietary technology to connect providers with experienced and certified wound care specialists who can care for patients virtually or via in-person visits. The Wound Company partners with health plans, home care companies, and providers to bring dignity to patients with wounds and ostomies while increasing positive patient outcomes.

This article was originally published here

Venturis Therapeutics, Inc. Announces Affiliation With David G. Armstrong DPM MD PhD Leading Authority on Diabetic Foot

David G. Armstrong, DPM, PhD, is an internationally recognized leader in the field of podiatric surgery, diabetic foot, limb preservation, and wound healing.

DALLAS, TX, USA, June 12, 2023/ — Venturis Therapeutics, Inc. (“VT” or the “Company”) announces that David G Armstrong, DPM MD PhD will assume the role of senior academic advisor for the surgeon board. This agreement was consummated following a review of the Company’s scientific and commercial opportunities.

Armstrong is the foremost expert in diabetic limb preservation and is recognized worldwide with a huge following through his prodigious authorship and lectures on diabetic limb salvage. This affiliation will further enhance the diabetic wound program and clinical research trials being undertaken by VT, and will improve the visibility of the Company dramatically among all those in the greater biotech wound healing community.

Venturis Therapeutics, Inc. is a biopharmaceutical company developing protein drug candidates to address diseases such as severe coronary heart disease, diabetic wounds, peripheral artery disease, erectile dysfunction, stroke, and spinal disk disease. The active pharmaceutical ingredient (“API”) in our drug candidates is FGF-1, a human protein that stimulates the growth of new blood vessels, thereby increasing the blood supply to ischemic organs and tissues.

This news release contains forward-looking statements that involve risks and uncertainties. Actual results and outcomes may differ materially from those discussed or anticipated. For example, statements regarding expectations for new research, progress with clinical trials or future business initiatives are forward looking statements. Factors that might affect actual outcomes include, but are not limited to, FDA approval of VT drug candidates, market acceptance of VT products by customers, new developments in the industry, future revenues, future expenses, future margins, cash usage, and financial performance. Additionally, until VT is cash flow positive from operations, the Company is dependent upon raising capital to fund its operations and meet its obligations as they come due. There can be no assurance that VT will be able to raise the necessary capital when needed.

Amy Gordon
Venturis Therapeutics Inc
+1 972-904-2029
email us here

Dr. David G Armstrong The 18th Malvern Diabetic Foot Conference Future of Wound Treatment

Digital Innovation Initiative Aims to Reduce Amputations

RALEIGH, N.C.–(BUSINESS WIRE)–In the United States alone, a leg is amputated every two minutes. As announced at last week’s New Cardiovascular Horizons (NCVH) Annual Conference, this confronting statistic is being met head on by a digital innovation initiative referred to as SL2 for “Saving Limbs. Savings Lives.” Enrollment in SL2 is now open to all members of the American Podiatric Medical Association (APMA), the country’s largest non-profit organization dedicated to advancing the practice of foot and ankle medicine.

APMA members will have access to CarePICS, a software application purpose built to support best practices in wound care, including electronic consults and electronic referrals for optimal collaboration with peers in the vascular community. As an added benefit, many of the activities facilitated within CarePICS are eligible for reimbursement. The application may be used via mobile phones, desktop computers and iPads/tablets. It does not require any special devices.

For more information on SL2 and to enroll, visit

The nationwide launch of SL2 is considered Phase 2 of the digital innovation initiative, with Phase 1 having drawn to a close at the end of May 2023, following a successful six-month pilot in Florida and Texas. Phase 2 will run for 12 months, through June 2023, at which time the potential for a permanent program will be evaluated.

The steadily increasing rate of lower extremity amputations in the United States – an estimated 60% deemed preventable – is shown to be the result of four key variables: (1) imprecise wound assessment and measurement (using manual tools), (2) inadequate and inconsistent wound documentation, (3) suboptimal patient follow-up and communication, and (4) fragmented coordination between providers who encounter wounds, such as podiatrists, and vascular specialists who treat associated medical conditions, mainly peripheral arterial disease (PAD) and critical limb ischemia (CLI). SL2 is positioned to combat these variables through a combination of digital tools, educational courses, data analysis and member support.

“When we look broadly at the medical histories of patients who have undergone lower extremity amputations, the evidence reveals that only about half have ever had a vascular evaluation or were referred to a vascular specialist. Their condition simply progressed to a stage where the limb could not be salvaged,” says Dr. Timothy Yates of Palm Vascular Centers, who participated in Phase 1 of SL2. “This is exactly the scenario SL2 is helping avoid. Using the CarePICS app, podiatrists can quickly and easily request an electronic consult with a vascular specialist, then convert it to an electronic referral when it’s indicated that the patient needs a vascular evaluation.”

“The CarePICS app has been a game changer for our wound care practice,” says Dr. Eric Lullove of West Boca Center for Wound Care, who also participated in Phase 1 of SL2. “Not only can we achieve precision and efficiency in our wound measurement and documentation, our patients can message with us, they can upload images, even participate in televisits. It is also possible to order wound dressings and cellular tissue products through the app.”

SL2 is governed by an advisory panel of physicians with expertise in podiatric and vascular medicine (in alphabetical order):

  • David B. Alper, DPM
    Member of Board of Trustees, American Podiatric Medical Association
    Board Member, American Diabetes Association – Northeast Region
  • M. Laiq Raja, MD, FACC, FSCAI
    Director and Co-Founder, Pulse Amputation Prevention Centers
    Interventional Cardiologist and Limb Salvage Specialist, El Paso Cardiology Associates, P.A.
    Medical Director of Cardiology and Critical Limb Ischemia Program, The Hospitals of Providence Memorial Campus

The SL2 advisory panel is directed by Christopher K. Bromley, DPM, FACFAS, Chief Medical Officer of CarePICS and Adjunct Professor at Kent State University College of Podiatric Medicine.

About CarePICS
CarePICS is a health tech company on a mission to save limbs and save lives through efficient, high-value digital tools purpose built to foster best practices in wound care, including precision measurement, compliant documentation, patient self-reporting, and streamlined collaboration among all providers in the continuum. CarePICS may be used in podiatry, vascular medicine, primary care, endocrinology, cardiology, oncology, plastic surgery, dermatology, geriatrics and myriad other clinical disciplines. The software platform serves as the backbone of two nationwide programs aimed at reducing preventable lower extremity amputations: SL2 and Collaborate4Wounds. CarePICS was founded by Paul Schubert and Terry Williams, both industry veterans of wound care and healthcare technology innovation. For more information, visit


Joy Efron, Principal
Kibit Marketing

The Most Positive Thing to Happen to Negative Pressure Wound Therapy

NEXA NPWT System Launched in the USA

OCEANSIDE, Calif.June 7, 2023 /PRNewswire/ — AOTI Inc, the global leader in multi-modality topical wound oxygen, announced exciting news from ongoing WOCNext conference in Las Vegas, Nevada, where their game changing NEXA Negative Pressure Wound Therapy (NPWT) system made its official USA debut.

The unique NEXA NPWT system is an incredibly flexible platform that is simple to use, silent, portable and affordable. NEXA seamlessly combines the simplicity of disposable NPWT with the performance features of more traditional durable NPWT technology platforms.

Dr. Mike Griffiths, CEO and President of AOTI commented; “Releasing the innovative NEXA NPWT platform in the USA is a major milestone for the company that will allow clinicians, payers, and patients alike to experience much improved performance at significantly lower cost. With NEXA, we have reimagined how NPWT should function.

Its addition to our portfolio only further enhances our mission of helping all people with chronic conditions get back to living their lives to the fullest.”

AOTI’s unique NEXA NPWT and Topical Wound Oxygen (TWO2) therapy are unlike any other treatment approaches. NEXA provided unrivaled flexibility and performance in a portable NPWT system. TWO2 is the only device that provides a multimodality treatment, combining higher pressure oxygen delivery with non-contact cyclical compression and humidity, in a therapeutic applied by the patient at home. This patented approach has been demonstrated in numerous Randomized Controlled Trial (RCT) and Real World Evidence (RWE) studies to not only heal chronic wounds at a far higher rate, but perhaps more importantly, keep them closed longer term, thereby reducing unnecessary hospitalizations and amputations.1, 2

1 Multinational, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Efficacy of Cyclical Topical Wound Oxygen (TWO2) Therapy in the Treatment of Chronic Diabetic Foot Ulcers; The TWO2 Study. Robert G. Frykberg et al, Diabetics Care 2020; 43:616-624.

Reduced Hospitalizations and Amputations in Patients with Diabetic Foot Ulcers Treated with Cyclical Pressurized Topical Wound Oxygen Therapy: Real-World Outcomes; Jessica Izhakoff Yellin, et al; Advances in Wound Care 2022;

About AOTI

AOTI is a privately-owned company based in Oceanside, California USA and Galway, Ireland that provides innovative solutions to resolve severe and chronic wounds worldwide. Our mission is to help all people with chronic conditions get back to living their lives to the fullest. We do this by enhancing access to care, improving quality of life and advancing health equity. 
Our products reduce healthcare costs and improve the quality of life for patients with these debilitating conditions. Our patented Topical Wound Oxygen (TWO2) at home therapy is clinically proven to deliver Sustained Wound Healing that reduces both Amputations and Hospitalizations, So Life Can Get Back to Normal.

For more information see:

Dr. Mike Griffiths
CEO & President
(760) 672 1920


Challenges faced by individuals living with foot and wound disease.

Foot and wound chronic disease is characterized by persistent ulcers, sores, and infections that primarily affect the feet. it is a condition that causes pain, affects mobility issues, and even long-term disability if left untreated. On today’s health beat, we delve deeper into the challenges faced by individuals living with foot and wound disease.

Placental Based Allografts: From Womb to Wound

In this webcast, Dr. Vincent W. Li reviews the biology of placental based allografts and the components relevant to wound healing, regeneration, and tissue repair. From May 2, 2019

To learn more about how amnio allografts can benefit your patients with chronic wounds as well as reimbursement information schedule a meeting at or call (336) 223-5050

DDI tackles diabetic foot complications

Dasman Diabetes Institute (DDI), established by the Kuwait Foundation for the Advancement of Sciences, held recently its specialized three-day course on the prevention and management of diabetic foot complications, in collaboration with the Primary Health Care Department at the Ministry of Health who assisted in coordinating this course. The program was held at the Institute…

Sonoma Pharmaceuticals Introduces Next Generation Solution for Pulse Lavage Irrigation in the European Union

BOULDER, CO / ACCESSWIRE / June 8, 2023 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, dermatology, and eye, oral and nasal care, today announced a new application for intraoperative pulse lavage irrigation treatment, which can replace commonly used IV bags in a variety of surgical procedures.

Sonoma developed this new application of its wound care technology in response to an unmet need for a non-toxic irrigation solution that can prevent infection and improve healing time. The intraoperative pulse lavage container is designed to be used in combination with a pulse lavage irrigation device, or flush gun, for abdominal, laparoscopic, orthopedic, and periprosthetic procedures. This product replaces commonly used non-antimicrobial saline and aggressive rinsing solutions with safe and effective Microcyn® Technology. Microcyn® Technology assists in the reduction of microorganisms, is non-toxic, and has regenerative properties, making it critical in preventing infection and promoting wound healing. Sonoma’s pulse lavage container is also cost competitive with IV bags, the current standard of care.

Sonoma developed the intraoperative pulse lavage irrigation treatment in close collaboration with the medical community and Sonoma’s existing distribution partners in Europe and expects this new application will be met with wide acceptance. Sonoma is now accepting orders for the pulse lavage irrigation treatment solution, which is expected to be ready for commercial use in Europe in September 2023. Sonoma anticipates commercial launch in the U.S. in 2024.

“Sonoma continues to lead in the innovation of products that improve outcomes for people with wounds or injuries or who are needing surgery. We continue to see increased demand for our wound care products in Europe, and we are excited to expand our offerings to include this next generation irrigation solution to help people heal faster following surgery,” said Amy Trombly, CEO of Sonoma Pharmaceuticals.

For more information, or to pre-order our pulse lavage irrigation treatment solution in Europe, please contact

About Sonoma Pharmaceuticals, Inc.

Sonoma Pharmaceuticals is a global healthcare leader for developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye care, nasal care, oral care, dermatological conditions, animal health care and non-toxic disinfectants. The company’s products reduce infections, itch, pain, scarring and harmful inflammatory responses in a safe and effective manner. In-vitro and clinical studies of hypochlorous acid (HOCl) show it to have impressive antipruritic, antimicrobial, antiviral and anti-inflammatory properties. Sonoma’s stabilized HOCl immediately relieves itch and pain, kills pathogens and breaks down biofilm, does not sting or irritate skin, and oxygenates the cells in the area treated, assisting the body in its natural healing process. The company’s products are sold either directly or via partners in 55 countries worldwide and the company actively seeks new distribution partners. The company’s principal office is in Boulder, Colorado, with manufacturing operations in Guadalajara, Mexico. European marketing and sales are headquartered in Roermond, Netherlands. More information can be found at For partnership opportunities, please contact

Forward-Looking Statements

Except for historical information herein, matters set forth in this press release are forward-looking within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including statements about the commercial and technology progress and future financial performance of Sonoma Pharmaceuticals, Inc. and its subsidiaries (the “company”). These forward-looking statements are identified by the use of words such as “continue,” “develop,” “anticipate,” “expect” and “expand,” among others. Forward-looking statements in this press release are subject to certain risks and uncertainties inherent in the company’s business that could cause actual results to vary, including such risks that regulatory clinical and guideline developments may change, scientific data may not be sufficient to meet regulatory standards or receipt of required regulatory clearances or approvals, clinical results may not be replicated in actual patient settings, protection offered by the company’s patents and patent applications may be challenged, invalidated or circumvented by its competitors, the available market for the company’s products will not be as large as expected, the company’s products will not be able to penetrate one or more targeted markets, revenues will not be sufficient to meet the company’s cash needs, fund further development, as well as uncertainties relative to the COVID-19 pandemic and economic development, varying product formulations and a multitude of diverse regulatory and marketing requirements in different countries and municipalities, and other risks detailed from time to time in the company’s filings with the Securities and Exchange Commission. The company disclaims any obligation to update these forward-looking statements, except as required by law.

Sonoma Pharmaceuticals™ and Microcyn® are trademarks or registered trademarks of Sonoma Pharmaceuticals, Inc. All other trademarks and service marks are the property of their respective owners.

Media and Investor Contact:

Sonoma Pharmaceuticals, Inc.

SOURCE: Sonoma Pharmaceuticals, Inc.

Wirelessly-powered ‘smart bandage’ could provide drug-free wound care


A new generation of wirelessly-powered, environmentally-friendly ‘smart bandages’ could help patients with non-healing wounds avoid infections, scientists say. The bandage could help improve the quality of life of people who live with chronic non-healing wounds, which currently frequently require painful cleaning and treatment. Non-healing wounds can be a side effect of certain medications or health factors like diabetes, cancer or damaged blood vessels. The smart bandage is built on technology initially developed by Dr Mahmoud Wagih of the James Watt School of Engineering and his colleagues from the University of Southampton. The research is showcased in a second paper, recently published in IEEE Transactions on Industrial Electronics. The paper demonstrates the first use of magnetic-resonant wireless power transfer to provide electricity to standard textiles using embroidery or screen printing – a feature which helped to make the smart bandage possible. In this case, the power was supplied to a newly-developed flexible electronic resistor made from silver and carbon which was printed into a textile surface to act as a wearable heating element. The system was capable of being heated to up to 60◦C while separated from the transmitter by 2cm at an efficiency exceeding 50%.

Swift Medical Announces Proven Outcomes Across 20 Million Wound Assessments

Swift’s AI-powered wound imaging technology shown to improve quality of care and costs to manage complex patients

June 01, 2023 09:00 AM Eastern Daylight Time
TORONTO–(BUSINESS WIRE)–Swift Medical, a digital health technology company focused on improving clinical and economic outcomes in wound care, today announced proven outcomes from more than 20 million wound assessments captured with Swift’s leading, AI-powered wound care platform. Deployed in nearly 4,000 healthcare facilities across North America, Swift’s technology has been shown to speed up wound healing by 37%, reduce wound prevalence and hospitalizations by 35% and 14%, respectively, and reduce hospital length of stay by 62%.

“We are proud to share the incredible impact our technology is having on the millions of patients living with wounds – one of today’s most expensive and overlooked threats to patients and our overall healthcare system”

Tweet this
“We are proud to share the incredible impact our technology is having on the millions of patients living with wounds – one of today’s most expensive and overlooked threats to patients and our overall healthcare system,” said Brian Litten, CEO of Swift Medical. “These outcomes demonstrate the impact of having the most powerful wound image dataset in the world and its ability to deliver high quality wound care with reduced costs.”

The Swift Skin & Wound mobile application enables any mobile device to be equipped with AI-powered imaging capabilities to capture clinically validated, high-precision 3D images, measurements, and other clinical data. The imaging captured at the point of care enables real-time, at-risk patient monitoring, proactive decision-making, and remote wound consultations, reducing the time and cost spent evaluating wounds to create a more efficient wound care experience for both clinicians and patients.

Today, more people suffer from chronic wounds than those with breast cancer, colon cancer, lung cancer, and leukemia combined. Despite this costly, growing problem, the current standard of care is outdated and highly inaccurate. Clinicians typically receive less than 10 hours of formal education and rely on paper rulers for measurements and cotton swabs for depth assessment. This inefficient and ineffective approach is both painful for patients and leads to poor diagnostic accuracy, prolonged healing, and inappropriate selection of therapies, putting patients at greater risk for readmission, longer lengths of stay and higher care costs.

With its advanced analytics and proven outcomes, Swift is now poised to partner with health plans and risk-bearing providers to deliver high quality, value-based wound care at scale.

About Swift Medical

Swift Medical is the global leader in digital wound care. We are headquartered in Toronto, with operations expanding across the U.S. and Canada. Our mission is to make empathy-driven wound care ubiquitous through AI-powered diagnostic technology. We are the trusted wound technology partner of more than 4,000 healthcare facilities in North America across the continuum of care. Our solutions empower healthcare providers to deliver standardized, accessible and equitable wound care for every patient – with advanced, high-precision imaging, compliant documentation, clinical analytics and remote care. To learn more about Swift Medical, visit us at


David Mannion

New Expert Guidelines from IWGDF Highlight the Growing International Recognition of Topical


Oxygen Therapy for Diabetic Foot Ulcers


Evidence-based recommendations support the effective use of TOT in diabetic foot ulcer management, revolutionizing treatment approaches worldwide

CAMBRIDGE, EnglandMay 17, 2023 /PRNewswire/ — NATROX® Wound Care, a leading innovator in wound care technology, proudly announces the release of newly published expert recommendations on the use of topical oxygen therapy for wound healing1. The updated guidelines endorse topical oxygen therapy (TOT) as an adjunct therapy in the treatment of diabetic foot ulcers (DFUs) 1. With its endorsement by leading experts, this ground-breaking therapy is poised to transform the lives of millions of people worldwide, offering renewed hope for effective healing and improved quality of life.

New IWDGF Guidelines
The International Working Group on the Diabetic Foot (IWGDF) has just published its 2023 Guidelines. This set of recommended DFU interventions, developed by a panel of renowned experts, serves as a trusted resource for healthcare professionals worldwide.

Notably, among the 29 recommendations highlighted, TOT gained recognition as an accepted intervention when treating non-healing DFUs. Consider the use of topical oxygen as an adjunct therapy to standard of care for wound healing in people with diabetes-related foot ulcers where standard of care alone has failed and resources exist to support this intervention1.”  With its inclusion in the IWGDF guidelines, topical oxygen therapy emerges as a vital tool, poised to revolutionize the management and healing of foot ulcers in individuals with diabetes.

In addition, the guidelines note that evidence on topical oxygen has substantially expanded in the last four years with several new RCTs with a total of ten included in the systematic review for these guidelines (References 100-109) 1, which includes an RCT study published in 2021² which compared the healing effects of using standard care against a combination of standard care plus NATROX® O₂ topical oxygen therapy. In the study, patients completing the therapy experienced 71% greater healing rates² and 73% greater reduction in wound size² with NATROX® O₂.

Experts recommend updating algorithms to include TOT
In the Journal of Wound Care, experts reached a “clear consensus that adjunctive treatments with a solid evidence base, including NPWT and TOT, must be included3 in each of the four proposed regional guidelines. Most notably, the experts agreed that “all hard-to-heal wounds are likely to benefit from TOT³.”

TOT received “A grade” from the American Diabetes Association
The American Diabetes Association recently released its “Standards of Care in Diabetes⁴” which not only recommended TOT as an adjunctive therapy for chronic DFUs, but also gave it an “A grade” based on the quality of evidence⁴. The newly published recommendations acknowledge the remarkable potential of TOT⁴.

According to Dr. Windy Cole, DPM, CWSP, FAPWH, FACCWS, renowned authority in podiatric medicine and dedicated wound care advocate for over two decades, “The evidence supporting the efficacy of TOT is now undeniable. It is imperative that healthcare professionals embrace this innovative yet simple approach to achieve improved healing outcomes.”  After witnessing the positive impact topical oxygen therapy can have on healing DFUs in her own clinic, Windy recently joined the NATROX® team as Director of Global Medical Affairs to further advocate for the integration of topical oxygen therapy in the treatment pathway for chronic wounds.

NATROX® Wound Care CEO, Craig Kennedy, expressed great enthusiasm regarding the recognition and international acceptance of topical oxygen therapy, stating, “We’re delighted that topical oxygen therapy continues to gain international recognition, cementing its status as a game-changing treatment in wound care. The inclusion of topical oxygen in the IWGDF Guidelines further validates our mission to transform the quality of life for patients suffering from chronic wounds, particularly those with diabetic foot ulcers.”

What is NATROX® O₂ Topical Oxygen Therapy NATROX® Wound Care manufactures an award-winning5,6,7 topical oxygen therapy device known as NATROX® O₂The compact, wearable device generates and delivers a continuous flow of oxygen directly to the wound bed to promote accelerated healing and foster a healthy wound environment. Its non-invasive nature, coupled with its remarkable effectiveness², offers a significant advancement in chronic wound treatment, even allowing patients to be treated from the comfort of home.

To learn about NATROX® O₂ and request a demo, visit:

About NATROX® Wound Care 
NATROX® Wound Care is an Inotec AMD brand. The specialist wound care company based in Cambridge, England was formed specifically to introduce new technologies to healthcare professionals around the world to promote faster and better healing to patients. The company’s flagship product, NATROX® O₂, is positioned to become an integral part of global wound care treatment regimes in the coming years. To learn more, explore the website:

See the references:

Media Contact:

NATROX® Wound Care 
Nancy Stahulak
VP Global Marketing 
+1 (888) 354 9772

Topical Oxygen Therapy Awarded Positive Treatment Recommendation by the International

Working Group on the Diabetic Foot in their 2023 Diabetic Foot Ulcer Guidelines   OCEANSIDE, Calif., May 15, 2023 /PRNewswire/ — AOTI Inc, the global leader in multi-modality topical wound oxygen, announced exciting news from the 9th International Symposium on the Diabetic Foot (ISDF). The ISDF is often referred to as the Olympics of the Diabetic Foot, due…

Largest Published Real-World Wound Imaging Study Reports MolecuLight®

led to Wound Treatment Plan Changes in up to 53% Cases   Results from 211 Facilities Show MolecuLight Imaging is a Valuable Toolin Improving Bacterial Infection Management TORONTO, May 23, 2023 /PRNewswire/ – MolecuLight Inc., the leader in point-of-care fluorescence imaging that locates and detects elevated, pathogenic bacterial loads in and around wounds, announced the publication of their…

Aurealis Therapeutics receives CTA approval for AUP-16 Phase 2 RCT in Diabetic Foot Ulcer patients

Multi-center, randomized, placebo-controlled diabetic foot ulcer (DFU) Phase 2 study to start May 2023 in Italy, Germany, and Poland After completing 12 months follow-up of our DFU Phase 1 study, and 10M CHF Series A financing round to accelerate our clinical program, these are fantastic news for the company”— Juha Yrjänheikki, CEO BASEL, SWITZERLAND, May…

Microbion Corp. Presents a Poster on Pravibismane’s Activity Against Diabetic Foot Infection Patient Isolates

  • Poster highlights pravibismane’s MIC activity in testing against aerobic and anaerobic pathogens isolated from diabetic foot infection patients
  • Pravibismane demonstrated potent, broad-spectrum activity against a wide range
    of pathogens, including MRSA, MSSA, and P. aeruginosa

BOZEMAN, Mont., May 10, 2023 /PRNewswire/ – Microbion Corporation today announced that the company presented a poster focusing on pravibismane’s activity against diabetic foot ulcer infection pathogens at the 9th International Symposium on the Diabetic Foot that is currently ongoing from May 10th to 13th, 2023 at The Hague, Netherlands. The poster highlights pravibismane’s activity versus comparator antibiotics against pathogens isolated from diabetic foot infection (DFI) patients in an earlier Phase 1b clinical study.

Poster Details:
Representative image (CNW Group/Microbion Corporation)

Representative image (CNW Group/Microbion Corporation)

Title: Broad-Spectrum, Potent Activity of Pravibismane Versus Comparators Against Diabetic Foot Ulcer Infection Patient Isolates Collected in a Phase 1b Study

Presenter: Dr. Jeff Millard, CSO

Poster Highlights:
  • Most common pathogens isolated from DFI subjects (N = 44) at baseline were: methicillin-susceptible Staphylococcus aureus [MSSA (25%)]; methicillin-resistant Staphylococcus aureus [MRSA (18.2%)]; Enterococcus faecalis (13.6%); and Pseudomonas aeruginosa (11.4%).
  • Mean pravibismane minimum inhibitory concentration (MIC) (µg/mL) for S. aureus MSSA was 0.21, S. aureus MRSA was 0.17, E. faecalis was 2.53, and P. aeruginosa was 1.43.
  • Mean pravibismane MICs for 12 of the 13 anaerobic bacteria was ≤1 µg/mL, including against Finegoldia magna and Anaerococcus spp.
  • Pravibismane exhibited similar or lower MIC relative to a panel of comparator antibiotics, including (but not limited to) levofloxacin, linezolid, clindamycin, and piperacillin-tazobactam, against Gram-positive and Gram-negative, susceptible and resistant, aerobes and anaerobes.

"We are pleased that pravibismane demonstrated extremely potent MIC activity against clinical DFI isolates, which was in line with in vitro AST microbial pre-clinical studies," said Dr. Jeff Millard, CSO of Microbion Corp. "Diabetic foot infections are often infected by several different bacterial species concurrently, which may change over the chronicity of the wound, from predominantly aerobic to anaerobic. We believe pravibismane’s potent broad-spectrum activity is potentially a key treatment advantage since a single agent could eradicate both aerobic and anaerobic bacteria, thereby decreasing the need for multiple systemic therapies."

Bacterial cultures for this study were grown from swabs collected at the wound bed at baseline visit and antimicrobial susceptibility testing (AST) was performed on isolated pathogens. Pathogen isolation and AST was performed at Investigational Health Management Associates (IHMA, IL), using the Clinical & Laboratory Standards Institute (CLSI) standard methods.

Topical pravibismane has received QIDP and Fast Track drug designation from the US FDA for the adjunctive treatment of moderate and severe diabetic foot ulcer infections. Topical pravbismane is currently enrolling in a Phase 2 clinical study to further evaluate its safety and efficacy in subjects suffering from moderate infections associated with chronic diabetic foot ulcers.

About Microbion

Microbion is a clinical-stage pharmaceutical company developing a new class of therapeutic compounds to improve the lives of patients with rare and serious diseases. Microbion’s lead drug candidate, pravibismane, is the first product in this new class and has multiple novel modes of action offering unique potential to address the unmet needs of chronic and severe health conditions. Topical/local pravibismane is in Phase 2 development for the treatment of chronic wounds and orthopedic infections. The Company is advancing inhaled pravibismane in Phase 1 clinical development for the treatment of chronic lung diseases, including non-tuberculous mycobacteria (NTM) and cystic fibrosis-related lung infections. Pravibismane has received backing from the Cystic Fibrosis Foundation, NIH, US DoD, and CARB-X with over $21 million in grants. The FDA has granted pravibismane with Orphan Drug, Fast Track, and QIDP designations.

For more information visit:

Safe Harbor Statement

Certain of the statements made in this press release are forward-looking, such as those, among others, relating to the success of clinical development of pravibismane and preparation for potential commercialization. These statements are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including, but not limited to, risks and uncertainties related to: our ability to enroll patients in our clinical trials at the pace that we project; the size and growth of the potential markets for pravibismane or any future product candidates and our ability to serve those markets; our ability to obtain and maintain regulatory approval of pravibismane or any future product candidates; and our expectations regarding the potential safety, efficacy or clinical utility of pravibismane or any future product candidates. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Microbion Corporation disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

SOURCE Microbion Corporation

CūtisCare Launches Third Annual Hyperbaric Aware™ National Campaign To Elevate Awareness Of Hyperbaric Oxygen Therapy

BOCA RATON, Fla., May 1, 2023 /PRNewswire/ — Hyperbaric Awareness USA™, a CutisCare initiative, has designated May Hyperbaric Awareness Month and is proud to announce the launch of the third annual Hyperbaric Aware™ national campaign to elevate awareness of hyperbaric oxygen therapy (HBOT). CutisCare launches a Hyperbaric Awareness USA campaign to elevate the awareness of hyperbaric oxygen…

MolecuLight Featured in Unprecedented 24 Presentations and Posters at European

Wound Management Association (EWMA) 2023 Annual Conference Wide-Spread Clinical Evidence using the MolecuLight Imaging Platform Reveals its Significant Global Adoption and Proven Utility in Wound Care TORONTO and MILAN, May 3, 2023 /PRNewswire/ – MolecuLight Inc., the leader in point-of-care fluorescence imaging that detects and locates elevated bacterial loads in wounds, announces that its MolecuLight wound imaging platform is featured in an unprecedented…

Two 3M Veraflo Therapy dressings receive first-ever FDA clearance for hydromechanical removal of non-viable tissue

Innovative therapy shown to help promote healing and reduce the need for surgical debridements creating potential savings for health care systems. ST. PAUL, Minn., April 27, 2023 /PRNewswire/ — 3M Health Care’s innovative 3M™ Veraflo™ Therapy, with both 3M™ Veraflo™ Cleanse Choice Complete™ Dressing and 3M™ V.A.C. Veraflo Cleanse Choice™ Dressing, received the first-ever Food and Drug Administration (FDA)…

Nevro Announces Enrollment of First Patient in PDN Sensory Study

First Randomized Controlled Trial Specifically Powered to Assess Restoration of Neurological Function in Patients with Intractable Painful Diabetic Neuropathy Breakthrough Device Designation Provides Expedited Review for Marketing Application to Expand Nevro’s FDA Labeling REDWOOD CITY, Calif., April 24, 2023 /PRNewswire/ — Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment…

New Publication Reveals MolecuLight Imaging Significantly Improved

Detection of Bacterial Burden Across Patients of All Skin Tones Findings show that MolecuLight is an Objective and Equitable Diagnostic Technology Positioned to Help Level Racial Disparity in Wound Care Outcomes TORONTO, April 25, 2023 /PRNewswire/ – MolecuLight Inc., the leader in point-of-care fluorescence imaging that locates and detects elevated bacterial loads in and around wounds,…

Army R&D selects local biotech firm to prevent wound infection

Press release from MLM Biologics Inc.


GAINESVILLE, Fla. – The U.S. Army Medical Research and Development Command (USAMRDC) recently awarded MLM Biologics, Inc. almost $1.5 million to develop a device to prevent infection in battlefield wounds. The device will incorporate MLM Biologic’s proprietary collagen processing and stabilization technologies.


MLM Biologics competed for the award in the battlefield treatment area, focused on preventing infection in wounds from “…complex, traumatic, penetrating injuries in a far-forward, austere environment.”


“We’re honored to bring our innovative solutions to the men and women who stand in harm’s way as our focus has always been on wound closure—not just wound management,” says CEO Chandra Nataraj.


As part of the award, MLM Biologics will develop a new medical device using its proprietary technologies combined with proven anti-inflammatory and anti-microbial components, Nataraj said. He believes it will eventually be available for civilian clinical use.


“We expect to make a difference, not only for our military heroes but eventually for everyone dealing with possible wound infection. The potential health benefits are huge,” Nataraj says.


The company maintains labs at the University of Florida’s business incubator, UF Innovate | Accelerate @ Sid Martin Biotech, where it conducts product development activities. Karl R. LaPan, UF Innovate | Accelerate director, believes MLM Biologics represents the tangible benefits incubators provide.


“MLM Biologics, and the development of a treatment to prevent wound infection, is a great example of public-private partnerships translating research into meaningful, life-changing products for America’s service members,” LaPan said.


The award is part of the Military Prototype Advancement Initiative, funded by the Department of Defense and issued through the Medical Technology Enterprise Consortium, a collaboration of industry and academia to facilitate R&D activities with USAMRDC and other government agencies.


About MLM Biologics, Inc.

MLM Biologics is a privately held medical device company specializing in the design, manufacture, and marketing of biologic medical devices. The company was founded on the modern interpretation of the Gandhian economic principle of “More for Less for Many.” It currently distributes an FDA-cleared wound care device (bio-ConneKt® Wound Matrix) out of its ISO-13485-certified facility in Gainesville, Fla. For more information, visit

An Alternate Explanation

A 48-year-old man with long-standing type 2 diabetes mellitus and chronic kidney disease presented with a 3-month history of numbness, tingling, and faint violaceous discoloration of the tips of multiple fingers and toes. Tom Alsaigh, M.D., Gurpreet Dhaliwal, M.D., Eri Fukaya, M.D., Ph.D., Nicholas J. Leeper, M.D., and Nazish Sayed, M.D., Ph.D.

MolecuLight Successfully Completes SOC 2® Type l Audit and Accreditation

Successful completion of recent audit demonstrates
MolecuLight’s commitment to data security


TORONTO, April 19, 2023 /PRNewswire/ – MolecuLight Inc., the leader in point-of-care fluorescence imaging that locates and detects elevated bacterial loads in and around wounds, announced that it is in compliance with SOC 2® Type I, having successfully completed its audit in accordance with the American Institute of Certified Public Accountants (AICPA) standards for Systems and Organization Controls (SOC). This enables MolecuLight to better serve the needs of its customers globally by ensuring the Company’s data management practices and organizational controls meet the highest international standards.


SOC ll (CNW Group/MolecuLight)

SOC ll (CNW Group/MolecuLight)

MolecuLight’s compliance with SOC 2® standards validates that the company has implemented controls relevant to the security, availability, and processing integrity of the systems used to process users’ data as well as the confidentiality and privacy of the information.


“Obtaining the SOC 2 certification reinforces MolecuLight’s ongoing commitment to the security, availability, and processing integrity of MolecuLight’s point-of-care fluorescence imaging technologies,” said Anil Amlani, MolecuLight’s CEO. “Our certification demonstrates our commitment and our business processes to maintain the highest level of security, privacy, availability, and confidentiality for our customers.”


As part of the process for achieving SOC 2® compliance, MolecuLight worked with PwC, an accredited auditor to review the design and operating effectiveness of the controls on its core MolecuLightDX® imaging platform against the applicable Trust Services Criteria for Security, Availability, and Confidentiality. These included the operating software of the imaging platform, how the devices manage customer and user data, as well as security policies and procedures. Over the course of the audit, MolecuLight demonstrated the ability to safely manage customers’ data and use of the platform, as well as its security controls and processes.


The MolecuLight i:X® and DX are the only imaging devices for the real-time detection of elevated bacterial burden in wounds that are FDA cleared and CE and Health Canada approved. With clinical evidence including over 75 peer-reviewed publications involving 1,600 patients, they are used by leading wound care facilities globally.


About MolecuLight Inc.
MolecuLight Inc. is a privately-owned medical imaging company that has developed and is commercializing its proprietary fluorescent imaging platform technology in multiple clinical markets. MolecuLight ‘s suite of commercial devices, which include the MolecuLight i:X® and DX™ fluorescence imaging systems and their accessories, are point-of-care handheld imaging devices for the real-time detection and localization of bacterial load in wounds and digital wound measurement. MolecuLight procedures performed in the United States benefit from an available reimbursement pathway which includes two CPT® codes for physician work to perform “fluorescence imaging for bacterial presence, location, and load” and facility payment for Hospital Outpatient Department (HOPD) and Ambulatory Surgical Center (ASC) settings through an Ambulatory Payment Classification (APC) assignment. The company is also commercializing its unique fluorescence imaging platform technology for other global markets with relevant unmet needs in food safety, consumer cosmetics and other key industrial markets.


For more information, contact:

Rob Sandler
Chief Marketing Officer
MolecuLight Inc.
T. +1.647.362.4684


Title: MolecuLight Successfully Completes SOC 2® Type l Audit and Accreditation
Download image:

SOURCE MolecuLight

Diabetic Wound Care (video)

Wound Problem After Below Knee Amputation Treated with new age creams (boric acid and Hypericum perforatum ( Sarı kantaron ), Calendula officinalis , Neem oil ( Azadirachta indica ) and Centellin.

Recommendations for Wounds After Flaps and Grafts

Michael Desvigne, MD, FACS, CWS, FACCWS Dr. Desvigne will present practical examples and case studies regarding the treatment of flaps and grafts after procedures, such as metatarsal amputation and the treatment of non-healing wounds. Dr. Desvigne will also discuss tools and methods he has used in the treatment of these amputation sites and non-healing wounds.

Managing the Landscape of Wound Types Working from a Comprehensive Algorithm

Vickie R. Driver, DPM, MS, FACFAS System Wide Medical Director INOVA Wound Healing and Hyperbaric Centers Falls Church Virginia Barry University , Miami Shores Florida Anderson Island, WA Daniel L. Kapp, MD Plastic Surgeon Daniel Kapp MD Plastic Surgery and Wound Care West Palm Beach, Florida Andrew J. Rader, DPM, FAENS, FACFAOM, FASPS, FAPWCA, FACCWS…



Both organizations call on physicians to assist Veterans.

PENSACOLA, Fla. , Feb. 27, 2023 /PRNewswire/ — Regenative Labs (Regenative), a leading HCT/P manufacturer, is partnering with Brothers in Arms Foundation (BIAF), a 501©3 nonprofit providing logistical and financial support to wounded, ill, injured and fallen Marines, sailors, and the families of those who served. Together, both organizations are dedicated to giving back and improving the quality of life for those who have served our country.


Regenative will donate approximately $5 million dollars of its state-of-the-art Wharton’s Jelly product, ProText™, to BIAF which will facilitate the care of qualifying veterans. To bring this care to veterans, Regenative and BIAF need the help of physicians to apply the product.


Physicians across the country may join in supporting our veterans by making a qualified donation of their time under the Brothers in Arms Foundation 501©3 non-profit.


“We’re extremely proud of this partnership,” shared Regenative Labs CEO, Tyler Barrett. “Ultimately our products are about improving patient quality of life. My grandfather served in the Marines in Korea, and so being able to serve those like him in unison with the mission of Brothers in Arms is important to me,” Barrett concluded.


Regenative’s Wharton’s Jelly product is a structural connective tissue allograft intended for homologous use to replace or supplement missing or damaged tissue directly at the site of a structural defect. Some doctors have used the product for muscle and cartilage tears and to replace missing or damaged tissue due to wounds and tissue defects, instead of masking the underlying connective tissue issue.


Regenative has been tracking patient outcomes of applications of their product for over two years. Retrospectively, the results have shown improvements greater than 33 percent in patient reported WOMAC improvement.


It is Regenative’s and BIAF’s goal to provide veterans with the best quality of life possible.


“We’re committed to bettering the quality of life for our veterans,” said Brothers in Arms Foundation President, Phillip Noblin. “This new, innovative treatment will give them the hope and support needed to heal. The partnership with Regenative Labs will further our mission of serving those who’ve served us,” said Noblin.


Physicians interested in taking care of qualified veterans by donating their services through a 501©3 non-profit may visit:

Veterans who wish to learn more, or to refer their physician today may visit:


One can make a monetary donation through the BIAF.


About Regenative Labs: Regenative Labs produces regenerative medicine products to address the root cause of a patient’s conditions using Wharton’s Jelly innovations rather than masking the pain with other treatments. Regenative Labs works closely with scientists, physicians, hospitals, and surgery centers to constantly monitor and improve patient progress and outcomes for new product development. Formed by veteran industry professionals familiar with daily challenges of innovations in healthcare, the company provides non-addictive, non-invasive options for patients. Regenative Labs’ expert product research and development team complies with FDA guidelines of minimal manipulation for homologous use. The company adheres to AATB and FDA guidelines. Learn more at Regenative’s website:


About Brothers in Arms Foundation: Brothers in Arms Foundation is a 501c3 non-profit founded in 2009 that exists to provide financial and logistical support to wounded, ill, injured and fallen Marines, sailors, and the families of those who served within the Marines Special Operations community. Over the years, the foundation has supported active-duty Marines, sailors, veterans and military families with programs and services ranging from financial assistance, funding vocational and quality of life initiatives, as well as funeral support and childcare. Learn more at:


SOURCE Regenative Labs

Wound Masterclass | Emerging Technologies in Clinical Practice

Yuanwen Jiang, Artem Trotsyuk, Simiao Niu, Dominic Henn, Kellen Chen, Chien-Chung Shih, Madelyn R. Larson, Alana M. Mermin-Bunnell, Smiti Mittal, Jian-Cheng Lai, Aref Saberi, Ethan Beard, Serena Jing, Donglai Zhong, Sydney R. Steele, Kefan Sun, Tanish Jain, Eric Zhao, Christopher R. Neimeth, Willian G. Viana, Jing Tang, Dharshan Sivaraj, Jagannath Padmanabhan, Melanie Rodrigues, David P.…